Nastaran Rahimi

Nastaran Rahimi

Auto-generated profile, based on publicly available information

Nastaran Rahimi

Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2016 in Scientific Reports
Verified
Journal Article
Open access
SFSara Fathollah
Sara Fathollah
SMShahriar Mirpour
Shahriar Mirpour
PMParvin Mansouri
Parvin Mansouri
ADAhmad reza Dehpour
Ahmad reza Dehpour
MGMahmood Ghoranneviss
Mahmood Ghoranneviss
KCKatalin Martits Chalangari
Katalin Martits Chalangari
It is estimated that 15 percent of individuals with diabetes mellitus suffer from diabetic ulcers worldwide. The aim of this study is to present a non-thermal atmospheric plasma treatment as a novel therapy for diabetic wounds. The plasma consists of ionized helium gas that is produced by a high-voltage (8 kV) and high-frequency (6 kHz) power supply. Diabetes was induced in rats via an intravascular injection of streptozotocin. The plasma was then introduced to artificial xerograph wounds in the rats for 10 minutes. Immunohistochemistry assays was performed to determine the level of transforming growth factor (TGF-β1) cytokine. The results showed a low healing rate in the diabetic wounds compared with the wound-healing rate in non-diabetic animals (P < 0.05). Moreover, the results noted that plasma enhanced the wound-healing rate in the non-diabetic rats (P < 0.05) and significant wound contraction occurred after the plasma treatment compared with untreated diabetic wounds (P < 0.05). Histological analyses revealed the formation of an epidermis layer, neovascularization and cell proliferation. The plasma treatment also resulted in the release of TGF-β1 cytokine from cells in the tissue medium. The findings of this study demonstrate the effect of plasma treatment for wound healing in diabetic rats.

29 June 2018 in Spinal Cord
Verified
Journal Article
Open access
PDF file
KAKhashayar Afshari
Khashayar Afshari
ADAmir Dehdashtian
Amir Dehdashtian
NHNazgol-Sadat Haddadi
Nazgol-Sadat Haddadi
Arvin Haj-MirzaianArvin Haj-Mirzaian
Arvin Haj-Mirzaian
AIArad Iranmehr
Arad Iranmehr
ADAhmad reza Dehpour
Ahmad reza Dehpour
This is an animal study. Metformin is a safe drug for controlling blood sugar in diabetes. It has been shown that metformin improves locomotor recovery after spinal cord injury (SCI). Neuropathic pain is also a disturbing component of SCI. It is indicated that metformin has neuroprotective and anti-inflammatory effects, which attenuate neuropathic pain and hyperalgesia in injured nerves. Thus, we evaluated metformin’s therapeutic effects on SCI neuroinflammation and its sensory and locomotor complications. Meanwhile, results were compared to minocycline, an anti-neuroinflammation therapy in SCI. Experimental Medicine Research Center, Tehran University of Medical Sciences, Iran In an animal model of SCI, 48 male rats were subjected to T9 vertebra laminectomy. Animals were divided into a SHAM-operated group and five treatment groups. The treatments included normal saline as a vehicle control group, minocycline 90 mg/kg and metformin at the doses of 10, 50 and 100 mg/kg. Locomotor scaling, behavioral tests for neuropathic pain and weight changes were evaluated and compared through a 28-days period. At the end of the study, tissue samples were taken to assess neuroinflammatory changes. Metformin 50 mg/kg improved the locomotors ability (p < 0.001) and decreased sensitivity to mechanical and thermal allodynia (p < 0.01). These results were compatible with minocycline effect on SCI (p > 0.05). While metformin led to weight loss, both metformin and minocycline significantly decreased neuroinflammation in the assessment of cord tissue histopathology, and levels of TNF-α and interleukin-1β (p < 0.001). Metformin could be considered as an alternative therapeutic agent for SCI, as it potentially attenuates neuroinflammation, sensory and locomotor complications of cord injury.

28 October 2016 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
APAlireza Partoazar
Alireza Partoazar
SNSanaz Nasoohi
Sanaz Nasoohi
SRSayed M. Rezayat
Sayed M. Rezayat
KGKambiz Gilani
Kambiz Gilani
SMShahram E. Mehr
Shahram E. Mehr
ADAhmad reza Dehpour
Ahmad reza Dehpour

1 July 2018 in NeuroToxicology
Verified
Journal Article
Closed access
MKMina Khalilzadeh
Mina Khalilzadeh
GPGhodratollah Panahi
Ghodratollah Panahi
ARAmir Rashidian
Amir Rashidian
MHMohammad-Reza Hadian
Mohammad-Reza Hadian
AAAlireza Abdollahi
Alireza Abdollahi
ADAhmad reza Dehpour
Ahmad reza Dehpour

1 February 2017 in European Journal of Pharmacology
Verified
Journal Article
Closed access
FYFatemeh Yarmohmmadi
Fatemeh Yarmohmmadi
NRNastaran Rahimi
Nastaran Rahimi
HFHedyeh Faghir-Ghanesefat
Hedyeh Faghir-Ghanesefat
NJNina Javadian
Nina Javadian
AAAlireza Abdollahi
Alireza Abdollahi
ADAhmad reza Dehpour
Ahmad reza Dehpour

1 November 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PDPegah Dejban
Pegah Dejban
FEFaezeh Eslami
Faezeh Eslami
NRNastaran Rahimi
Nastaran Rahimi
NTNasrin Takzare
Nasrin Takzare
MJMohamadmostafa Jahansouz
Mohamadmostafa Jahansouz
ADAhmad Reza Dehpour
Ahmad Reza Dehpour